Local Anesthetic Lidocaine Xylocaine CAS 137-58-6 Pharmaceutical Raw Powder

Lidocaine Profile

CAS: 137-58-6 

MF: C14H22N2O 

MW: 234.34 

EINECS: 205-302-8 

Purity: 99%min. 

Properties: Powder 

Payment: T/T, Western Union, MoneyGram, Bitcoin 

Delivery Time: Within 24 Hours 

Delivery Mode: EXPRESS Door To Door 

Usage: Medical clinical commonly used local anesthetic

Pharmacology and toxicology

This product is amide local anesthetic. Blood absorption or intravenous administration of the central nervous system have obvious excitement and inhibition of biphasic effects, and can be without the excitement of the pioneer, low blood concentration, the emergence of analgesia and drowsiness, increased pain threshold; with the dose plus Large, role or toxicity enhancement, sub-toxic plasma concentrations of anticonvulsant effect; when the plasma concentration of more than 5mg/ml-1 can occur convulsions. This product at low doses, can promote myocardial K + outflow, reduce myocardial autonomy, and has anti-ventricular arrhythmias; at the therapeutic dose, the electrical activity of myocardial cells, atrioventricular conduction and myocardial contraction without Significantly affect; plasma concentration further increased, can cause heart conduction velocity, atrioventricular block, inhibition of myocardial contractility and cardiac output decreased.

Clinical application

For acute myocardial infarction, surgery, digitalis poisoning and cardiac catheterization-induced acute ventricular arrhythmias, including ventricular premature beats, ventricular tachycardia and ventricular fibrillation. Followed by the state of epilepsy is also used for other anticonvulsants ineffective and local or spinal anesthesia. Can also ease the tinnitus.

1. The efficacy profile of lidocaine as a local anesthetic is characterized by a rapid onset of action and intermediate duration of efficacy. Therefore, lidocaine is suitable for infiltration, block, and surface anesthesia. Longer-acting substances such asbupivacaine are sometimes given preference for subdural and epidural anesthesias; lidocaine, though, has the advantage of a rapid onset of action. Epinephrine (adrenaline) vasoconstricts arteries, reducing bleeding and also delays the resorption of lidocaine, almost doubling the duration of anaesthesia. For surface anesthesia, several available formulations can be used e.g. for endoscopies, before intubations, etc. Buffering the pH of lidocaine makes local freezing less painful.Lidocaine drops can be used on the eyes for short ophthalmic procedures.

2. Topical lidocaine has been shown in some patients to relieve the pain of postherpetic neuralgia (a complication of shingles), though not enough study evidence exists to recommend it as a first-line treatment.ntravenous lidocaine also has uses as a temporary fix for tinnitus. Although not completely curing the disorder, it has been shown to reduce the effects by around two-thirds.

3. Lidocaine is also the most important class-1b antiarrhythmic drug; it is used intravenously for the treatment of ventricular arrhythmias (for acute myocardial infarction, digoxin poisoning, cardioversion, or cardiac catheterization) if amiodarone is not available or contraindicated. Lidocaine should be given for this indication after defibrillation, CPR, and vasopressors have been initiated. A routine prophylactic administration is no longer recommended for acute cardiac infarction; the overall benefit of this measure is not convincing.